Cannabis Law Report

MARCH 19, 2020

Products containing cannabidiol (CBD), ranging from gummies to lotions and oils, continue to grow both in popularity and presence in the marketplace. Food and Drug Administration,” (CBD Report) and provided additional updates on its evaluation of the risks and benefits of CBD products. 18 March 2020. Arnold & Porter.

CBD

Cannabis Law Report

MAY 6, 2022

Since 2015, the FDA has sent warning letters to companies allegedly illegally selling unapproved cannabinoid (CBD) products. The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. CBD and Delta-8 THC products are produced and marketed in a largely unregulated marketplace.

THC

Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. United States Disclaimer.

Extraction

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., First Patient Expected to be Enrolled by Q2 of 2022.

Clinical Trials

Dykema (Cannabis Law Blog)

MARCH 25, 2020

According to state-released data, those patients purchased approximately $1.7 Unlike 18 of the 23 jurisdictions who have medical marijuana statutes , an individual cannot qualify for a registry identification card in Illinois if they have only “chronic pain.” At that point, Illinois had roughly 3,300 patients.

Chronic Pain

Cannabis Law Report

DECEMBER 8, 2021

This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. For more information, please visit www.virpaxpharma.com. Christopher M.

Clinical Trials

Cannabis Law Report

NOVEMBER 10, 2021

The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 About Virpax Pharmaceuticals.

Research and Development

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Chief Scientific Officer. About MyMD Pharmaceuticals, Inc.

Clinical Trials

Cannabis Law Report

OCTOBER 6, 2021

Preliminary in-vitro, ex-vivo, and in-vivo data demonstrated that AnQlar inhibits replication of SARS-CoV-2 and may inhibit viral spread as well as viral brain load at non-toxic concentrations. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Betsy Brod.

Research and Development

Veriheal

OCTOBER 5, 2020

These compounds mostly include cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) amongst many others such as cannabigerol (CBG). Edibles are also known as cannabis-infused foods and refer to a food product that contains the compounds from the cannabis plant. Summary of Hawaiian Cannabis Regulations.

Edibles

Cannabis Law Report

OCTOBER 1, 2021

Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. About Noble Capital Markets, Inc.

Research and Development

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical

Puff Puff Post

SEPTEMBER 16, 2019

Event details below: Date: Tuesday, September 17th 2019. The clinical care team is comprised of family physicians and specialists in chronic pain , cancer, gastroenterology, and endocrinology, as well as nurses with clinical expertise in cannabis medicine. Time: 9:00AM to 5:00PM. ABOUT SPECTRUM THERAPEUTICS.

Programs

Cannabis Law Report

OCTOBER 26, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 1 Data published by Research and Markets, March 2018. For more information, visit www.mymd.com. MyMD: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com. Arthritis Foundation: Greta Barnes.

Pharmaceutical

Cannabis Law Report

DECEMBER 14, 2021

There are 28 million people suffering from chronic pain in the UK and this range of formulations offers pain doctors the best and most comprehensive selection of cannabinoid treatment options for their patients. to bring innovation and precision to the growing UK medical cannabis market. About Columbia Care International.

Extraction

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. for its MET for the nasal delivery of cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults.

Pharmaceutical

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Data collection. 2016 ; Sznitman et al. years (Atakan 2012 ).

Research and Development

Green Relief

MAY 13, 2018

The benefits of CBD-rich cannabis concentrates for chronic traumatic encephalopathy (CTE) are well-known among football players and other pro athletes. Preclinical research and anecdotal accounts indicate that CBD is highly active against brain ischemia, modulating many of the molecular hallmarks of TBI pathology. But the U.S.

THC

Cannabis Law Report

OCTOBER 17, 2019

Retailers such as Walgreens, CVS, Rite Aid, Kroger, Safeway, Nordstrom, and DSW are selling or plan to sell CBD-infused topical lotions, cosmetics, and even edibles where they are legally able to do so. Not only are makers of foods, health and beauty products, and supplements interested in CBD and THC.

Law